Xanthelasma and arginine vasopressin deficiency (central diabetes insipidus), think Erdheim Chester disease
- 8 October 2024
- journal article
- editorial
- Published by BMJ in BMJ Case Reports
- Vol. 17 (10) , e261021
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Erdheim‐Chester disease with long‐standing diabetes insipidus and generalized edemaClinical Case Reports, 2021
- Pituitary Imaging Abnormalities and Related Endocrine Disorders in Erdheim–Chester DiseaseCancers, 2021
- Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester diseaseHematology-American Society Hematology Education Program, 2020
- Prevalence of Hypothyroidism in Patients With Erdheim-Chester DiseaseJAMA Network Open, 2020
- Association of BRAF V600E with Hypothalamic-Pituitary-Adrenal Axis Involvement in Erdheim-Chester DiseaseEndocrine and Metabolic Science, 2020
- Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraBlood, 2020
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell HistiocytosisJAMA Oncology, 2018
- Thoracic, abdominal and musculoskeletal involvement in Erdheim-Chester disease: CT, MR and PET imaging findingsInsights into Imaging, 2014